The new capabilities feature state-of-the-art technology for efficient manufacturing and optimised output.
The $60m-plus investment was largely funded by the Biomedical Advanced Research and Development Authority (BARDA) to strengthen the resilience of the US pharmaceutical supply chain and ensure reliable domestic production of critical primary packaging.
The expansion significantly increases the site’s annual production capacity for core vials, while more than tripling local capacity for high-value solutions.
“The expansion contributes to SCHOTT Pharma’s long-term global growth strategy, with a strong local-for-local presence in the US and scaled manufacturing capacity for high-value solutions that address key trends in the pharmaceutical industry, such as biologic medications and novel drug formulations,” says Christian Mias, CEO of SCHOTT Pharma.
Pushing high-value solutions in the US
In addition to installing a significant number of new high-end converting lines for core borosilicate glass vials, the expansion in Lebanon included major infrastructure modernisation, line upgrades,and new state-of-the-art technology to increase the capacity for high-value solutions.
These include the RTU vial platform adaptiQ and EVERIC pure vials.
“We would like to express our sincere gratitude to the Biomedical Advanced Research and Development Authority for supporting the expansion of our US-based manufacturing footprint."
"With its new advanced equipment, our site in Pennsylvania is strengthening supply chain resilience in the US and ensuring the availability of primary packaging for critical life-saving therapies for patients throughout our nation," says Christopher Cassidy, President of SCHOTT Pharma USA.
The Lebanon site is one of only two SCHOTT Pharma locations worldwide capable of manufacturing EVERIC pure vials, which feature high chemical durability, a homogeneous inner surface and tight dimensional tolerances to ensure high drug stability throughout its shelf-life.
It is also the only SCHOTT Pharma site producing adaptiQ prewashed, presterilised RTU vials, supplying these high-performance containers across the US and globally.
Addressing key pharma trends
Speciality vials, which are part of SCHOTT Pharma’s high-value solutions portfolio, play a critical role in storing a wide range of sensitive medications.
These include sensitive biologics and biosimilars, emergency medications and vaccines. The vials are also used for innovative drugs or therapies that require lyophilisation to remain stable, such as antibody-drug-conjugates (ADCs) for targeted cancer treatments.
In RTU configuration, SCHOTT Pharma’s vials also support the industry’s manufacturing shift toward ready-to-use primary packaging.
This approach enables faster, more flexible, and more efficient drug filling for pharmaceutical companies and contract manufacturing organisations (CMOs), while simultaneously enhancing drug safety and simplifying regulatory compliance.
